Table 2 Univariate Cox analysis of prognostic factors associated with survival for patients with locally advanced cervical cancer who underwent neoadjuvant chemotherapy and radical hysterectomy

Age (years)

1.01

0.98–1.04

0.505

1.01

0.98–1.04

0.390

1.01

0.98–1.03

0.642

Body mass index (kg/m²)

1.14

0.99–1.31

0.064

1.12

0.98–1.29

0.105

1.05

0.92–1.19

0.470

Serum creatinine (μmol/l)

1.00

0.98–1.02

0.810

1.01

0.99–1.03

0.618

1.00

0.99–1.02

0.737

Tumor stage (IIA2 vs. IB2)

1.15

0.73–1.83

0.541

1.15

0.71–1.84

0.576

0.97

0.64–1.47

0.873

Histology (non-squamous vs. squamous)

1.69

0.98–2.91

0.059

1.84

1.06–3.19

0.029

1.91

1.19–3.08

0.008

Tumor differentiation (G3 vs. G1–2)

1.49

0.72–3.11

0.285

1.81

0.90–3.65

0.098

1.50

0.78–2.90

0.228

Deep stromal invasion (yes vs. no)

1.95

1.09–3.50

0.025

2.09

1.16–3.77

0.014

2.19

1.30–3.68

0.003

LVSI (yes vs. no)

2.10

1.29–3.41

0.003

2.04

1.25–3.35

0.005

1.62

1.06–2.48

0.025

Positive margins (yes vs. no)

9.37

5.19–16.91

<0.0001

10.2

5.59–18.63

<0.0001

7.92

4.41–14.22

<0.0001

Positive nodes (yes vs. no)

7.13

4.09–12.44

<0.0001

7.55

4.25–13.42

<0.0001

4.81

3.07–7.54

<0.0001

Positive parametrium (yes vs. no)

10.88

5.68–20.87

<0.0001

11.83

6.11–22.87

<0.0001

9.19

4.81–17.55

<0.0001

 No

Reference

Reference

Reference

Reference

Reference

Reference

Reference

Reference

Reference

 HbA_1c < 7%

2.66

1.32–5.37

0.006

2.79

1.31–5.97

0.008

3.33

1.78–6.24

<0.0001

 HbA_1c ≥ 7%

6.02

3.63–9.96

<0.0001

7.13

4.17–12.17

<0.0001

7.01

4.44–11.06

<0.0001

 Hypertension (yes vs. no)

1.37

0.82–2.27

0.227

1.36

0.78–2.37

0.273

1.31

0.83–2.09

0.248

 Cardiovascular disease (yes vs. no)

1.09

0.47–2.52

0.837

0.47

0.18–1.19

0.109

1.11

0.54–2.31

0.770

 Metformin (yes vs. no)

1.21

0.65–2.24

0.552

0.88

0.46–1.68

0.705

1.86

1.13–3.07

0.015

 Complete response (yes vs. no)

0.52

0.33–0.82

0.005

0.50

0.31–0.83

0.007

0.69

0.45–1.06

0.089